DEPDC1B Antibody
| Code | Size | Price |
|---|
| PSI-8283-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-8283-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Storage:
DEPDC1B antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Documents
Further Information
Additional Names:
DEP domain-containing 1B, DEP1B, BRCC3, Breast cancer cell 3, XTP1
Application Note:
DEPDC1B antibody can be used for detection of DEPDC1B by Western blot at 1 - 2 μg/ml. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
The DEP domain-containing 1B (DEPDC1B) protein was initially identified as a radiation response biomarker in human lymphoblastoid cell lines (1). Like the related protein DEPDC1A, expression of DEPDC1B correlates with a poor prognosis in cancer patients (2,3). Studies have shown that DEPDC1B levels are upregulated in non-small cell lung cancer (NSCLC) and have an inverse correlation with patient survival. Ectopic expression of DEPDC1B in NSCLC activated Wnt/B-catenin signaling and enhanced cell migration and invasion while silencing DEPDC1B expression suppressed these traits (2).
Background References:
- Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010; 20:1482-92.
- Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/B-catenin signaling. Biochem. Biophys. Res. Commun. 2014; 450:899-905.
- Kassambara A, Schoenhals M, Moreaux J, et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One 2013; 8:e62752.
Buffer:
DEPDC1B antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (94%), Chicken: (88%)
Immunogen:
DEPDC1B antibody was raised against a 19 amino acid peptide near the carboxy terminus of human DEPDC1B.
The immunogen is located within the last 50 amino acids of DEPDC1B.
The immunogen is located within the last 50 amino acids of DEPDC1B.
NCBI Gene ID #:
55789
NCBI Official Name:
DEP domain containing 1B
NCBI Official Symbol:
DEPDC1B
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 58 kDa
Observed: 57 kDa
Observed: 57 kDa
Protein Accession #:
NP_060839
Protein GI Number:
223633999
Purification:
DEPDC1B antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
DEPDC1B antibody is human specific. At least two isoforms are known to exist; this antibody will only detect the largest isoform. DEPDC1B antibody is predicted to not cross-react with DEPDC1A.
Swissprot #:
Q8WUY9
User NOte:
Optimal dilutions for each application to be determined by the researcher.